Nitracrine (free base)

Orders received during 11/25~11/29 will be shipped in 11/30/2020 due to Thanksgiving holiday.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584319

CAS#: 4533-39-5 (free base)

Description: Nitracrine (free base) is an acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-11-25. Prices are subject to change without notice.

Nitracrine (free base) is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 584319
Name: Nitracrine (free base)
CAS#: 4533-39-5 (free base)
Chemical Formula: C18H20N4O2
Exact Mass: 324.1586
Molecular Weight: 324.384
Elemental Analysis: C, 66.65; H, 6.21; N, 17.27; O, 9.86

Related CAS #: 4533-39-5 (free base)   6514-85-8 (HCl)  

Synonym: Nitracrine (free base); C 283; CCRIS 1973

IUPAC/Chemical Name: 1-Nitro-9-(3'-dimethylaminopropylamino)-acridine


InChi Code: InChI=1S/C18H20N4O2/c1-21(2)12-6-11-19-18-13-7-3-4-8-14(13)20-15-9-5-10-16(17(15)18)22(23)24/h3-5,7-10H,6,11-12H2,1-2H3,(H,19,20)

SMILES Code: CN(CCCNC1=C(C([N+]([O-])=O)=CC=C2)C2=NC3=CC=CC=C31)C

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Niemira M, Dastych J, Mazerska Z. Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia. Biochem Pharmacol. 2013 Jul 15;86(2):231-41. doi: 10.1016/j.bcp.2013.05.008. Epub 2013 May 18. PubMed PMID: 23688499.

2: Wilson WR, Thompson LH, Anderson RF, Denny WA. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. J Med Chem. 1989 Jan;32(1):31-8. PubMed PMID: 2909741.

3: Siim BG, Hicks KO, Pullen SM, van Zijl PL, Denny WA, Wilson WR. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem Pharmacol. 2000 Oct 1;60(7):969-78. PubMed PMID: 10974206.

4: Szumiel I, Walicka M. Cytotoxicity and the effect of combined treatment with X-rays of an anticancer 1-nitro-9-aminoacridine derivative in L5178Y-R and L5178Y-S cells. Neoplasma. 1980;27(6):697-702. PubMed PMID: 7254425.

5: Tadi K, Ashok BT, Chen Y, Banerjee D, Wysocka-Skrzela B, Konopa J, Darzynkiewicz Z, Tiwari RK. Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer. Cancer Biol Ther. 2007 Oct;6(10):1632-7. Epub 2007 Jul 24. Erratum in: Cancer Biol Ther. 2008 Mar;7(3):479. PubMed PMID: 17921700; PubMed Central PMCID: PMC4134887.

6: Robertson IG, Bland TJ, Palmer BD. Effect of substituents on the metabolism of nitracrine in rat. Xenobiotica. 1996 May;26(5):559-69. PubMed PMID: 8736066.

7: Ferguson LR, Denny WA, O'Rourke SM. Mutagenic activity of nitracrine derivatives in Salmonella typhimurium: relationship to drug physicochemical parameters, and to bacterial uvrB and recA genes and plasmid pKM101. Mutat Res. 1989 May;223(1):13-22. PubMed PMID: 2654627.

8: Wiśniewska A, Niemira M, Jagiełło K, Potęga A, Swist M, Henderson C, Skwarska A, Augustin E, Konopa J, Mazerska Z. Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells. Biochem Pharmacol. 2012 Jul 1;84(1):30-42. doi: 10.1016/j.bcp.2012.03.013. Epub 2012 Apr 6. PubMed PMID: 22484277.

9: Gniazdowski M. Mechanism of inhibition of DNA-dependent RNA synthesis in vitro by Ledakrin. Mater Med Pol. 1978 Jul-Sep;10(3):159-65. PubMed PMID: 723289.

10: Warwas M, Narczeuska B, Dobryszycka W. Blood serum peptidases in patients with ovarian carcinoma treated with Ledakrin. Arch Immunol Ther Exp (Warsz). 1977;25(2):235-42. PubMed PMID: 17375.

11: Oleszkiewicz L, Zarzycki J, Szroeder J, Dereń K. The effect of Ledacrin on elements of the lobulus in human liver. Acta Med Pol. 1979;20(4):445-6. PubMed PMID: 546115.

12: Roberts PB, Anderson RF, Wilson WR. Hypoxia-selective radiosensitization of mammalian cells by nitracrine, an electron-affinic DNA intercalator. Int J Radiat Biol Relat Stud Phys Chem Med. 1987 Apr;51(4):641-54. PubMed PMID: 3495509.

13: Kulczycka E, Krzyzowska-Gruca S, Marczyński B. Effects of some 9-aminoacridine derivatives on the nucleus and nucleolus. Ann Med Sect Pol Acad Sci. 1976;21(1-2):67-8. PubMed PMID: 952072.

14: Acheson RM, Taylor GN, Waring MJ, Haylock S, Abel G. The intercalative DNA binding and antitumor activity of some bis-acridines related to nitracrine. Chem Biol Interact. 1985 May;53(3):371-5. PubMed PMID: 4006013.

15: Radzikowski C. Antineoplastic activity of C-283 preparation (Ledakrin) in model experiments. Mater Med Pol. 1976 Jul-Sep;8(3):345-9. PubMed PMID: 1034860.

16: Ferguson LR, Turner PM, Denny WA. Mutagenicity of nitracrine analogues in Salmonella typhimurium: mutational specificity and activation by bacterial enzymes and rat-liver S9. Mutat Res. 1987 Jan;187(1):1-9. PubMed PMID: 3540655.

17: Bartoszek A, Dackiewicz P, Składanowski A, Konopa J. In vitro DNA crosslinking by Ledakrin, an antitumor derivative of 1-nitro-9-aminoacridine. Chem Biol Interact. 1997 Feb 28;103(2):141-51. PubMed PMID: 9055872.

18: Konopa J, Pawlak JW, Pawlak K. The mode of action of cytotoxic and antitumor 1-nitroacridines. III. In vivo interstrand cross-linking of DNA of mammalian or bacterial cells by 1-nitroacridines. Chem Biol Interact. 1983 Feb;43(2):175-97. PubMed PMID: 6402315.

19: Mazerska Z, Chołody M, Lukowicz J, Wysocka-Skrzela B, Ledóchowski A. Comparison of antitumor properties of nitracrine and amsacrine analogs. Arzneimittelforschung. 1987 Nov;37(11):1276-81. PubMed PMID: 3326605.

20: Daghastanli NA, Rossa MM, Selistre-De-Araujo HS, Tedesco AC, Borissevitch IE, Degterev IA. Cytotoxicity of nitroheterocyclic compounds, quinifuryl and nitracrine, towards leukaemic and normal cells on the dark and under illumination with visible light. J Photochem Photobiol B. 2004 Jul 19;75(1-2):27-32. PubMed PMID: 15246347.